ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) trial of its oral, selective pan-AKT inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and PIK3CA-related Overgrowth Spectrum disorders (PROS). The MOSAIC trial represents the first registrational trial of its kind for patients suffering from these rare genetic conditions characterized by mutations in the PI3K/AKT pathway that emerge in childhood and early adolescence.